Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

ASCO-GU 2023: The DEAR study

Darolutamide▼, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Nubeqa Header Image

Description

In this on-demand video, Professor Robert Jones gives an update on a congress highlight presented at the 2023 American Society of Clinical Oncology Genitourinary (ASCO-GU) Symposium. Professor Jones discusses the results of the DEAR study on the real-world utilisation and outcomes of darolutamide, enzalutamide, and apalutamide in patients with nmCRPC, including discontinuation data and data on progression to metastatic castration-resistant prostate cancer (mCRPC).

NUBEQA▼ Prescribing Information

Speakers
    • Professor Robert JonesProfessor Robert Jones

    Professor Jones is Director, Cancer Clinical Trials Unit for Scotland, professor of clinical cancer research at the University of Glasgow and a consultant medical oncologist at the Beatson West of Scotland Cancer Centre.

    After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials as well as collaborative translational research. He currently chairs the UK National Clinical Research Institute’s Bladder and Renal research group.

ASCO-GU 2023: ARASENS post-hoc analysis
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1297, February 2024
P3 Prostate Cancer Forum: Session 3
NUBEQA®▼ (darolutamide) | Xofigo®▼ (radium-223 dichloride)
PP-NUB-GB-1488, February 2024
BAUN 2022
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1314, February 2024

PP-NUB-GB-1296 | February 2024